Overview

A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine